Sort
10,766 grants matching “checkpoint inhibitor”
Advancing the translatability of mouse models for cancer immunotherapy
$720,801Rosemary J Akhurst · University Of California, San Francisco · R01 · FY2020 · CA
Mechanisms of cancer immunotherapy-associated thrombosis
$720,736Keith R. McCrae · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · HL
Depleting exosomes to improve responses to immune therapy in HNSCC
$720,532Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · DE
Mechanism and inhibition of SREBP-dependent cholesterol/lipid metabolism
$720,423Gerhard Wagner · Harvard Medical School · R01 · FY2014 · HL
Personalized precision dosing of biologic therapies in oncology
$720,363Bradley T Messmer · Abreos Biosciences, Inc. · R44 · FY2018 · CA
Systems genetics analysis of tumor evolution in the mouse
$720,018Allan Balmain · University Of California, San Francisco · R35 · FY2017 · CA
Rapid Diagnosis and Treatment Response Phenotyping of Immune Checkpoint Inhibitor-Associated Acute Interstitial Nephritis
$719,851Dennis G. Moledina · Yale University · R01 · FY2025 · DK
A Pathway for Necrotic Cell Death
$719,845David J Shapiro · University Of Illinois At Urbana-Champaign · R01 · FY2025 · CA
Elucidating the role of transcriptomics in driving ethnicity and ancestry-related disparities in colorectal cancer
$719,426Jane C. Figueiredo · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Functional and molecular consequences of SF3B1 mutations in human hematopoietic stem cells
$719,314Sergei Doulatov · Columbia University Health Sciences · R01 · FY2025 · HL
Clinical and Translational Investigations of Immune Suppression and Immune Modulation in Glioblastoma
$718,983Edjah Nduom · National Institute Of Neurological Disorders And Stroke · ZIA · FY2023 · NS
Imaging tumor and T cell responses to metabolic and immune modulation therapy
$718,818Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA
Depleting exosomes to improve responses to immune therapy in HNSCC
$718,185Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · U01 · FY2023 · DE
A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
$717,936Catherine Sibyl Diefenbach · New York University School Of Medicine · R01 · FY2022 · CA
Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis
$717,824David R Spriggs · Sloan-Kettering Inst Can Research · U01 · FY2009 · CA
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
$717,369Mark Yarchoan · Johns Hopkins University · R01 · FY2025 · CA
Targeting FGFR Alterations in Gastroesophageal Cancer
$716,314Sandra W Ryeom · Columbia University Health Sciences · R01 · FY2024 · CA
Implications of Changes in Islet Exosomal Cargo in Type 1 Diabetes
$715,816Emily K Sims · Indiana University Indianapolis · R01 · FY2022 · DK
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia
$715,641Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse events
$715,543Adam Mor · Columbia University Health Sciences · R01 · FY2025 · AI
Clinical trials employing cancer vaccine combination therapies
$715,531James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Mechanism of spontaneous and DSB-induced repair
$715,514Rodney J. Rothstein · Columbia University Health Sciences · R37 · FY2010 · GM
The Transmembrane Protein Disulfide Isomerase TMX1 Negatively Regulates Thrombosis
$714,505David W Essex · Temple Univ Of The Commonwealth · R01 · FY2023 · HL
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
$714,132Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2020 · CA
Novel Targets for Vaccine Therapy
$714,123Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2017 · CA